scholarly journals Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure

2021 ◽  
Author(s):  
Jennifer M. Coller ◽  
Fei Fei Gong ◽  
Michele McGrady ◽  
Louise Shiel ◽  
Danny Liew ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Symptomatic Heart Failure

Abstract 4954: Risk Factors for Death or Transplant in Chronic Symptomatic Heart Failure in Children: Subanalysis of Pediatric Carvedilol Study

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Elizabeth D Blume ◽  
Mark M Boucek ◽  
Daphne Hsu ◽  
Bernie LaSalle ◽  
Kimberlee Gauvreau ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Left Ventricle ◽  
Ejection Fraction ◽  
Study Trial ◽  
Older Age ◽  
Qualitative Assessment ◽  
Z Score ◽  
Symptomatic Heart Failure ◽  
Parametric Testing

The Pediatric Carvedilol Study trial offers a unique opportunity to investigate patient characteristics and risk factors associated with death or transplant in a population of children with moderate heart failure symptoms. The database from the Pediatric Carvedilol Study trial includes 157 children enrolled with symptomatic heart failure (NYHA II–IV) and ejection fraction (EF)<40%. For this analysis, the patients were divided into by outcome into 2 groups: those who died or underwent heart transplant during the study period (D/HTx) and those who did not (non-D/HTx). Baseline variables were compared using standard parametric and non-parametric testing. Multivariate analysis was performed using logistic regression Results: Of the 157 children, the median age at enrollment was 3 yrs (0.2–17.8yrs). Fifty-two percent were male, and 116/157 (74%) had a left ventricle (LV) as the systemic ventricle. All pts except 3 were NYHA/Ross class II-III, with a median EF of 25.7%, median BNP of 111, and median LVEDD z-score of 6.04. Overall incidence of D/HTx in the enrolled patients over the study period was 30/157 (19%), with 12 deaths and 18 transplants. Risk factors for D/HTx were older age (8.1yrs vs 2.1 yrs, p< 0.006), higher BNP levels at enrollment (250 vs 80, p<0.003) and worse AVV regurgitation (p<0.012), but not diagnosis of congenital heart disease, ventricular morphology, or qualitative assessment of systemic ventricular dysfunction. In the subgroup of patients with a systemic LV, the D/HTx group had a significantly larger EDD z-score (7.7 vs 5.8, p=0.05), but no difference in ejection fraction (25.9 vs 25.6, p=0.8) compared to the non D/HTx. In a multi-variate model after adjusting for age, LV EDD z-score and BNP at enrollment were significantly related to risk for D/HTx. For this pediatric population with chronic symptomatic heart failure, risk factors for death or transplant included older age, higher BNP, and AVVR. In the subgroup of patients with a systemic left ventricle, larger LV EDD z-score, but not lower EF, was significantly related to short term risk for death or transplant.

Trastuzumab-induced cardiotoxicity in Uruguayan HER2-positive breast cancer patients.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 143-143
Author(s):  
Andrea Schiavone ◽  
Mariana Diaz ◽  
Natalia Camejo ◽  
Natalia Reborido ◽  
Horacio Vazquez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Heart Failure ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Sedentary Lifestyle ◽  
High Cholesterol ◽  
Her2 Positive ◽  
Symptomatic Heart Failure ◽  
Irreversible Reduction

143 Background: To evaluate the incidence, severity and outcome of Trastuzumab-induced cardiotoxicity in HER2 positive Uruguayan breast cancer (BC) patients. Methods: Retrospective observational analysis of HER2 positive BC patients who were treated with Trastuzumab (TTZ) from January 2007 to December 2013 at two Uruguayan centers. Cardiac monitoring included physical examination and assessment of left ventricular ejection fraction (LVEF) by echocardiography that was evaluated before TTZ administration and every 12 weeks thereafter during the duration of therapy. Cardiovascular risk factors analyzed were: obesity (BMI ≥ 30 kg/m2), hypertension, diabetes, sedentary lifestyle and high cholesterol. Results: Sixty nine female patients were found in the databases of our institutions. Median age was 48 years (range: 27-73). Stage at diagnosis was as detailed: 19 % EI, 46 % EII, 29 % EIII and 4 % EIV. Eighty nine percent of patients received adjuvant TTZ , 4 % neoadjuvant TTZ and 7 % received it as a palliative therapy. Thirty patients (43, 5%) had at least one cardiovascular risk factors: 26% hypertension, 16% obesity, 9% sedentary lifestyle, and 4% high cholesterol. Median number of TTZ cycles was 15. Cycles were administered every 3 weeks at standard dose. Nineteen patients (27%) developed cardiotoxicity, of whom 12 had a transient suspension because of a reversible fall in LVEF, 2 had a irreversible reduction in LVEF, and 5 had a symptomatic heart failure. Eighty-nine percent of our patients (62 patients) completed treatment and the rest had a definitive suspension due to a irreversible reduction in LVEF or symptomatic heart failure. Most patients that developed cardiotoxicity (15 out of 19) had cardiovascular risk factors and also most of them (16 out of 19) had received anthracyclines before TTZ. Conclusions: Cardiotoxicity incidence was similar to the incidence reported in the literature and when it was present, in most cases was transient, asymptomatic, and reversible.

scholarly journals Incidence and risk factors for symptomatic heart failure after catheter ablation of atrial fibrillation and atrial flutter

EP Europace ◽  
2015 ◽  
Vol 18 (4) ◽  
pp. 521-530 ◽  
Author(s):  
Henry D. Huang ◽  
Jonathan W. Waks ◽  
Fernando M. Contreras-Valdes ◽  
Charles Haffajee ◽  
Alfred E. Buxton ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Atrial Flutter ◽  
Symptomatic Heart Failure

788 Risk factors for rehospitalization in the elderly with chronic heart failure with preserved and impaired systolic function

2007 ◽  
Vol 6 (1) ◽  
pp. 180-180
Author(s):  
S BOZINOVIC ◽  
A GRDINIC ◽  
D STAMENKOVIC ◽  
M STOJADINOVIC ◽  
I MARKOVIC ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Systolic Function ◽  
The Elderly

Prevalence and risk factors of leukocytosis among heart failure patients

2019 ◽  
pp. 468-473
Author(s):  
Ajaz Ahmad ◽  
Majid Alharbi ◽  
Omar Aldhabaan ◽  
Yazid Alzapni ◽  
Sultan Alanazi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Heart Failure Patients

Causes and associated risk factors of heart failure patients in Aljouf region of Saudi Arabia

2021 ◽  
pp. 185-189
Author(s):  
Md Sheikh ◽  
Manahel Alotaibi ◽  
Nouf Almutairi ◽  
Eid Aljohani ◽  
Omar Alruwaili ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Saudi Arabia ◽  
Heart Failure Patients ◽  
Associated Risk Factors

The Relation of Body Mass Index to Biochemical Parameters and Profile of Heart Failure

2018 ◽  
Vol 69 (7) ◽  
pp. 1673-1677
Author(s):  
Viviana Aursulesei ◽  
Andrei Manta ◽  
Razan Al Namat ◽  
Monica Hugianu ◽  
Angela Maria Moloce ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Body Mass Index ◽  
Body Mass ◽  
Patient Selection ◽  
Biochemical Parameters ◽  
Obesity Paradox ◽  
Lipid Levels ◽  
Randomized Control ◽  
Selection Parameters

The bidirectional relation between body mass index (BMI) and heart failure (HF) is complex and not fully understood. The obesity paradox phenomena is controversial and related to patient selection, parameters used for defining abnormal weight, characteristics of HF. Our study sustain the importance of controlling risk factors, in particular plasma glucose, lipid levels, as well as hypertension in patients with HF and BMI over 25 kg/m2. Also, in contrast to the randomized control studies our results can only partially support data related to obesity paradox phenomena.

Sign in / Sign up

Export Citation Format

Share Document